CDK4 and CDK6 kinases: From basic science to cancer therapy

被引：165

作者：

Fassl, Anne ^{[1
]}

Geng, Yan ^{[1
]}

Sicinski, Piotr ^{[1
]}

机构：

[1] Harvard Med Sch, Dana Farber Canc Inst, Blavatnik Inst, Dept Canc Biol,Dept Genet, Boston, MA 02215 USA

来源：

SCIENCE | 2022年 / 375卷 / 6577期

关键词：

CYCLIN-DEPENDENT KINASES; BREAST-CANCER; CELL-CYCLE; PHARMACOLOGICAL INHIBITION; TRANSCRIPTIONAL REGULATION; ACQUIRED-RESISTANCE; ANTITUMOR-ACTIVITY; ENDOCRINE THERAPY; OVARIAN-CANCER; INDUCED DEATH;

D O I：

10.1126/science.abc1495

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) and their activating partners, D-type cyclins, link the extracellular environment with the core cell cycle machinery. Constitutive activation of cyclin D-CDK4/6 represents the driving force of tumorigenesis in several cancer types. Small-molecule inhibitors of CDK4/6 have been used with great success in the treatment of hormone receptor-positive breast cancers and are in clinical trials for many other tumor types. Unexpectedly, recent work indicates that inhibition of CDK4/6 affects a wide range of cellular functions such as tumor cell metabolism and antitumor immunity. We discuss how recent advances in understanding CDK4/6 biology are opening new avenues for the future use of cyclin D-CDK4/6 inhibitors in cancer treatment.

引用

页码：158 / +

页数：20

共 50 条

[21] A NOVEL SUBSTRATE FOUND IN EPITHELIAL TYPE CELLS FOR CDK4 AND CDK6
KWON, TK
BUCHHOLZ, M
GABRIELSON, E
NORDIN, A
FASEB JOURNAL, 1995, 9 (04): : A1066 - A1066
[22] Transgenic mice to study the role of cyclin d dependent kinases, Cdk4 and Cdk6 in beta cell proliferation
不详
TRANSGENIC RESEARCH, 2005, 14 (04) : 516 - 517
[23] Mammalian cells cycle without the D-type cyclin-elependent kinases Cdk4 and Cdk6
Malumbres, M
Sotillo, R
Santamaria, D
Galán, J
Cerezo, A
Ortega, S
Dubus, P
Barbacid, M
CELL, 2004, 118 (04) : 493 - 504
[24] Tumor resistance to CDK4/6 inhibitors and degraders determined by the expression state of CDK6
Wu, Xuewei
Yang, Xiaobao
Xiong, Yan
Li, Ruitong
Ito, Takahiro
Ahmed, Tamer
Karoulia, Zoi
Adamopoulos, Christos
Wang, Hong
Wang, Li
Xie, Ling
Ueberheide, Beatrix
Aaronson, Stuart
Chen, Xian
Sellers, William
Buchanan, Sean
Jin, Jian
Poulikakos, Poulikos I.
CANCER RESEARCH, 2021, 81 (13)
[25] Distinct roles for Cdk4 and Cdk6 during B lymphocyte activation.
Tanguay, DA
Chiles, TC
FASEB JOURNAL, 1996, 10 (06): : 120 - 120
[26] BTX-9341, a bifunctional degrader of CDK4 and CDK6 for glioblastoma multiforme
Majeski, Hannah
Chahal, Kirti
Okano, Akinori
Pasis, Angela
Carlson, Casey
Shakya, Arvind
Liu, Qiao
Huang, Shenlin
Chourasia, Aparajita Hoskote
Fung, Leah
CANCER RESEARCH, 2023, 84 (06)
[27] Palbociclib (Cyclin-Dependent Kinases CDK4 and CDK6 Selective Inhibitor) Induced Grade 3 Interstitial Pneumonitis
Kunadharaju, R.
Saradna, A.
Ahmad, M.
Fuhrer, G.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
[28] Functional Genomic Analysis of CDK4 and CDK6 Gene Dependency across Human Cancer Cell Lines
Zhang, Zhouwei
Golomb, Lior
Meyerson, Matthew
CANCER RESEARCH, 2022, 82 (11) : 2171 - 2184
[29] CDK6 Immunophenotype Implicates Potential Therapeutic Application of CDK4/6 Inhibitors in Urothelial Carcinoma
Sun, Ran
Wang, Xuemei
Zhang, Leichao
Gu, Yu
Yang, Shaojuan
Wang, Liping
Wang, Xueju
FRONTIERS IN ONCOLOGY, 2022, 12
[30] Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders
Poulikakos, P.
Wu, X.
Yang, X.
Xiong, Y.
Ito, T.
Ahmed, T.
Karoulia, Z.
Adamopoulos, C.
Li, R.
Wang, H.
Wang, L.
Xie, L.
Liu, J.
Ueberheide, B.
Aaronson, S.
Chen, X.
Buchanan, S.
Sellers, W.
Jin, J.
EUROPEAN JOURNAL OF CANCER, 2020, 138 : S5 - S5

← 1 2 3 4 5 →